Effect of Probiotic and Synbiotic Oral Supplementation in Autoimmune Diseases: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
Nutrients · 30.03.2026 · 18 (7) · 1107
DOI: 10.3390/nu18071107 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Nutrients, online erschienen am 30.03.2026. Verfasst von Yuan-Yow Chiou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Nephrology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung Univers…. Hauptthemen laut MEDLINE: Autoimmune Diseases, Dietary Supplements, Probiotics, Synbiotics. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NSTC, NCKUH.
Abstract (Originalsprache)
Background
Autoimmune diseases affect 5–10% of the global population. Probiotic supplementation has emerged as a potential adjunctive therapy in managing inflammation associated with these conditions. This systematic review and meta-analysis aimed to examine the effectiveness of oral probiotics in patients with autoimmune diseases for managing inflammation.
Methods
A literature search of PubMed, EMBASE, and Cochrane CENTRAL was performed up to 18 June 2024. Eligible studies were randomized controlled trials (RCTs) examining the effects of oral supplementation of probiotics, synbiotics, or prebiotics in patients with established autoimmune diseases. The primary outcome was changes in inflammatory markers, including interleukin (IL)-6, IL-10, IL-1β, tumor necrosis factor (TNF)α, and high-sensitivity C-reactive protein (hs-CRP).
Results
Twelve RCTs involving 703 patients were included. Significant reductions were observed in levels of IL-6 (pooled standardized mean difference [pSMD] = −0.83; 95% confidence interval [CI]: −1.30, −0.37), IL-10 (pSMD = −0.30; 95% CI: −0.61, −0.00), TNFα (pSMD = −0.41; 95% CI: −0.77, −0.06), and hs-CRP (pSMD = −0.71; 95% CI: −1.18, −0.23) in patients taking probiotic supplementation. Subgroup analysis revealed that in rheumatoid arthritis (RA) patients, the probiotics group showed greater improvements in IL-6, IL-1β, and TNFα compared to the controls. In multiple sclerosis (MS) patients, the probiotics group demonstrated greater improvements in hs-CRP.
Conclusions
Oral probiotic supplementation lowers the levels of some inflammatory markers in patients with autoimmune diseases. Further studies with longer follow-up durations are needed to confirm these findings and explore the long-term benefits of probiotics in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Pediatric Nephrology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704302, Taiwan.
- Department of Psychology, Kaohsiung Medical University, Kaohsiung City 807378, Taiwan.
- Department of Senior Welfare and Services, Southern Taiwan University of Science and Technology, Tainan 710301, Taiwan.
Förderung
- NSTC
- NCKUH
Zitieren
APA
Chiou, Y. Y., Chiu, T. Y., & Chen, M. J. (2026). Effect of Probiotic and Synbiotic Oral Supplementation in Autoimmune Diseases: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 18(7), 1107. https://doi.org/10.3390/nu18071107
Vancouver
Chiou YY, Chiu TY, Chen MJ. Effect of Probiotic and Synbiotic Oral Supplementation in Autoimmune Diseases: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2026;18(7):1107. doi:10.3390/nu18071107
BibTeX
@article{Chiou2026,
author = {Chiou, Yuan-Yow and Chiu, Tsu-Yun and Chen, Mei-Ju},
title = {Effect of Probiotic and Synbiotic Oral Supplementation in Autoimmune Diseases: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {7},
pages = {1107},
doi = {10.3390/nu18071107}
}
EUVIMED